Alchemab Therapeutics
Focus: Alchemab Therapeutics is a UK-based biotech company specializing in human-derived antibodies as a therapeutic modality. The company is at Series A stage, positioning itself in the early-stage biotechnology space focused on antibody discovery and development.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
Funding Stage
SERIES A
Open Jobs
4+3 this month
Stable — net +3 jobs in 30d
4 added, 1 removed. Backfill posture.
Should You Work at Alchemab Therapeutics?
AI assessmentBest suited for early-stage scientists and technologists willing to trade stability for equity upside and platform-building opportunities in a capital-efficient, UK-based antibody company.
Why Work Here
- Ground-floor opportunity at a Series A antibody-focused biotech with differentiated human-derived antibody platform technology
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Alchemab Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.